Peter Attia· MD
and now effenakumab the regeneron ngptl3 monoclonal antibody so those four things constitute the state of the art therapy for homozygous FH it gets a lot of patience to relatively normal LDL levels
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and now effenakumab the regeneron ngptl3 monoclonal antibody so those four things constitute the state of the art therapy for homozygous FH it gets a lot of patience to relatively normal LDL levels
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
every nakumop is the golden rescue for these children it's still only used in adults but I hope that we will be able to use that quadruple therapy rapidly in kids also because it obviates the need for the lafaresis in many instances